Antibodies to Optic Nerve Glycosaminoglycans in Glaucoma
About the Research Project
Program
Award Type
Standard
Award Amount
$50,000
Active Dates
April 01, 1999 - March 31, 2001
Grant ID
G1999016
Summary
Although high intraocular pressure (IOP) is frequently associated with glaucoma, some people have the disease without high IOP. In these cases, it has been suggested that nerve death and damage to the optic nerve may result from a person’s own antibodies (autoimmunity) that mistakenly attack the optic nerve and/or its blood supply. Dr. Wax has provided evidence that some glaucoma patients have antibodies that interact with important molecules (called glycosaminoglycans) that help form support structures for the optic nerve. He will now perform a detailed analysis to further characterize the specificity of these antibodies and determine whether there are changes in the glycosaminoglycans of patients with the antibodies. In addition, he will correlate the extent of antibody reactivity to glycosaminoglycans with optic nerve damage. The goal of this study is to confirm the hypothesis that autoimmunity plays a role in glaucoma.
Related Grants
National Glaucoma Research
Developing New Drugs for Glaucoma
Active Dates
January 01, 2026 - December 31, 2027
Principal Investigator
Pete Williams, PhD
Current Organization
Karolinska Institutet
Developing New Drugs for Glaucoma
Active Dates
January 01, 2026 - December 31, 2027
Principal Investigator
Pete Williams, PhD
Current Organization
Karolinska Institutet
National Glaucoma Research
Developing a New Glaucoma Treatment That Avoids Daily Drops
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Gavin Roddy, MD, PhD
Current Organization
Mayo Clinic, Rochester
Developing a New Glaucoma Treatment That Avoids Daily Drops
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Gavin Roddy, MD, PhD
Current Organization
Mayo Clinic, Rochester
National Glaucoma Research
Human Retinal Regeneration to Cure Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Karl Wahlin, PhD
Current Organization
University of California, San Diego
Human Retinal Regeneration to Cure Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Karl Wahlin, PhD
Current Organization
University of California, San Diego